Harvard Medical School's Dr. Scott Shikora presents data from EnteroMedics ' ( ETRM +5.1% ) 28-patient DM2 ENABLE study assessing the feasibility of VBLOC vagal block therapy delivered via its Maestro RC System
Gainers: SGOC +30.4% . DGLY +21.67% . CREG +20.14% . RPRX +16.42% . ETRM +13.87% . LAS +13.23% . SCOK +10.71% . COBR +9.57% . TKMR +8.61% . SIG +5.65% . Losers: GOMO -20.19
By Life Sciences Report : Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report ,
EnteroMedics , Inc. (NASDAQ: ETRM ) Q2 2014 Earnings Conference Call August 7, 2014 11:00 a.m. ET Executives ..... business update. As a reminder, this conference call, as well as EnteroMedics ’ SEC filings and Web site at enteromedics .com, Complete Story
EnteroMedics (NASDAQ: ETRM ) Q2 results : Revenue: $0; Operating Expenses: $7.4M (+21.1%); Operating Loss: ($7.4M) (-21.1%); Net
EnteroMedics (NASDAQ: ETRM ): Q2 EPS of -$0.11 misses by $0.01 . Press Release Post your comment!
June 18 (Reuters) - EnteroMedics Inc's shares jumped about 37 percent in premarket trading on Wednesday, a day after an advisory panel to the U.S. Food and Drug Administration voted in favor of the...
We are no longer providing equity research on EnteroMedics ETRM . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
will be a significant obstacle for EnteroMedics . With limited reimbursement, Maestro ..... neurostimulation that leads to weight loss. EnteroMedics ' key patent that covers electrical ..... 16 million patients available to EnteroMedics .Even though Maestro's effectiveness
EnteroMedics ETRM posted third-quarter results that ..... value estimate unchanged. Although EnteroMedics has begun to roll out its Maestro system ..... until after 2017. In the meantime, EnteroMedics burned through another $5.6 million